Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Sep
18
Today In Oncology
AI’s Evolving Role in Clinical Care Enterprise-Wide
FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Zipalertinib Added to Chemotherapy Improves PFS in First-Line EGFR Exon 20 NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo